About Topigen Pharmaceuticals
Topigen Pharmaceuticals is a Healthcare company based in Montreal (Canada) founded in 2000. Respiratory disorder treatments are developed by this clinical-stage biopharmaceutical firm. Topigen Pharmaceuticals has raised $50.09 million across 4 funding rounds from investors including Desjardins, BDC and Caisse de depot et placement du Quebec. Topigen Pharmaceuticals offers products and services including Triglyceride Assay Kit, Antibodies, and Elisa Kits. Its focus areas include Life Sciences, Pulmonology, Drugs and COPD and Asthma.
Company details
TOPIGEN Pharmaceuticals was founded in 2000 in Montreal, Canada, as a clinical-stage biopharmaceutical company. Focus was placed on treatments for respiratory conditions such as asthma and COPD. The lead product, TPI ASM8, an oligonucleotide targeting inflammatory receptors, advanced to Phase 2 trials for moderate to severe asthma. TPI 1100 entered preclinical stages for COPD. Proprietary RNA-silencing and FANA oligonucleotide synthesis technologies were utilized. Acquisition by Pharmaxis occurred in January 2010.
- Headquarters Montreal, Canada
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website topigen.com
- Total Equity Funding$50.09M (USD)
in 4 rounds
- Latest Funding Round$25M (USD), Series C
Aug 2007
- InvestorsDesjardins
& 4 more
Products & Services of Topigen Pharmaceuticals
Topigen Pharmaceuticals offers a comprehensive portfolio of products and services, including Triglyceride Assay Kit, Antibodies, and Elisa Kits.
Enzymatic kit for precise triglyceride measurement in samples.
Proteins for detecting specific cellular targets in experiments.
Assays for quantifying proteins and molecules in biological samples.
Funding Insights of Topigen Pharmaceuticals
Topigen Pharmaceuticals has successfully raised a total of $50.09M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $25 million completed in August 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50.09M
- Total Rounds 4
- Last Round Series C — $25M
- First Round $20M
(Jun 2005)
- Investors Count 5
All 4 funding rounds of Topigen Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2007 | $25M | Series C | – | – | |
| Apr 2006 | $6M | Debt – Venture | – | – | |
| Oct 2005 | $5.09M | Series B | – | – | |
| Jun 2005 | $20M | Series B | – | – | – |
5 investors in total: 5 institutional.
Investors in Topigen Pharmaceuticals
Topigen Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Desjardins, BDC and Caisse de depot et placement du Quebec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech & Life-Sciences focused Growth stage Venture Debt Firm investing in North America | mmvf.com | Toronto, Canada | ||
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Investment strategies are provided across diverse asset classes and markets. | 1965 | cdpq.com | Quebec City, Canada | |
Commercial banking services for small and medium-sized enterprises are provided. | 1944 | bdc.ca | Montreal, Canada | |
Financial services are provided cooperatively to members in Canada. | 1900 | desjardins.com | Levis, Canada |
Investor details for Topigen Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Topigen Pharmaceuticals
3 dated milestones of Topigen Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Topigen Pharmaceuticals is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series C, of $25.0M.
Web traffic of Topigen Pharmaceuticals
The website of Topigen Pharmaceuticals (topigen.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 38% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Topigen Pharmaceuticals
Topigen Pharmaceuticals was founded in 2000 and raised its 1st funding round 5 years after it was founded.
Topigen Pharmaceuticals is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Topigen Pharmaceuticals is a funded company, having raised a total of $50.09M across 4 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Jun 2005.
TOPIGEN Pharmaceuticals was founded in 2000 in Montreal, Canada, as a clinical-stage biopharmaceutical company. Focus was placed on treatments for respiratory conditions such as asthma and COPD. The lead product, TPI ASM8, an oligonucleotide targeting inflammatory receptors, advanced to Phase 2 trials for moderate to severe asthma. TPI 1100 entered preclinical stages for COPD. Proprietary RNA-silencing and FANA oligonucleotide synthesis technologies were utilized. Acquisition by Pharmaxis occurred in January 2010.
Topigen Pharmaceuticals offers Triglyceride Assay Kit, Antibodies, and Elisa Kits.
Topigen Pharmaceuticals has 5 investors. Key investors include Desjardins, BDC, Caisse de depot et placement du Quebec, MMV Financial, and NovaQuest Capital Management.